CA-headquartered pharmaceutical company Amgen, announced plans to invest $200 million in 2025 to establish its new technology and innovation center in Hyderabad, southern India. CEO Robert Bradway made this announcement during the site’s inauguration on Monday, Feb 24, adding that significant additional investments are planned for future years.
The center, which was initially announced last year, will focus on leveraging artificial intelligence and data science to support the development of new medicines.
The Hyderabad facility is growing, with approximately 300 employees already working at the site. According to Som Chattopadhyay, Amgen’s national executive for India, the workforce is expected to expand to 2,000 employees by the end of the year.
Hyderabad hosted the BioAsia conference this week, featuring executives from major pharmaceutical companies including Amgen, Eli Lilly, Novartis, and several Indian pharmaceutical companies.
Amgen’s expansion aligns with a broader trend of global pharmaceutical companies increasing their footprint in India, which is often referred to as the “pharmacy of the world” due to its significant role in global drug manufacturing and distribution.
This development comes amid improving U.S.-India trade relations. Earlier this month, the United States and India agreed to initiate discussions for an early trade deal and work toward resolving their ongoing tariff disputes following talks between U.S. President Donald Trump and Indian Prime Minister Modi.
Jennifer Larson, U.S. Consul General in Hyderabad, highlighted the significance of this collaboration, noting that “One significant outcome was the launch of the U.S.-India trust initiative, which is to promote collaboration in critical and emerging technologies.” She described Amgen’s expansion as “a perfect example of how our nations can work together to harness innovation, talent and technology.”
However, these developments occur against the backdrop of potential trade challenges, as President Trump has indicated his intention to impose tariffs of “25% or higher” on pharmaceutical imports. Such measures could significantly impact Indian pharmaceutical companies, as the United States represents the largest market for most generic drug manufacturers.
Last updated: December 26th, 2025
